ResMed Inc. $RMD Shares Bought by Certuity LLC

Certuity LLC raised its position in ResMed Inc. (NYSE:RMD) by 561.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,736 shares of the medical equipment provider’s stock after acquiring an additional 5,718 shares during the quarter. Certuity LLC’s holdings in ResMed were worth $1,623,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Terra Nova Asset Management LLC grew its position in ResMed by 0.6% in the 3rd quarter. Terra Nova Asset Management LLC now owns 7,805 shares of the medical equipment provider’s stock valued at $2,136,000 after acquiring an additional 46 shares in the last quarter. NBT Bank N A NY grew its position in ResMed by 22.9% in the 3rd quarter. NBT Bank N A NY now owns 252 shares of the medical equipment provider’s stock valued at $69,000 after acquiring an additional 47 shares in the last quarter. IMA Advisory Services Inc. grew its position in shares of ResMed by 52.7% during the third quarter. IMA Advisory Services Inc. now owns 139 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 48 shares in the last quarter. Occidental Asset Management LLC grew its position in shares of ResMed by 3.0% during the fourth quarter. Occidental Asset Management LLC now owns 1,699 shares of the medical equipment provider’s stock worth $409,000 after buying an additional 49 shares in the last quarter. Finally, New Wave Wealth Advisors LLC grew its position in shares of ResMed by 2.8% during the third quarter. New Wave Wealth Advisors LLC now owns 1,899 shares of the medical equipment provider’s stock worth $520,000 after buying an additional 52 shares in the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $225.50, for a total value of $1,125,470.50. Following the completion of the sale, the chief executive officer owned 466,223 shares in the company, valued at approximately $105,133,286.50. The trade was a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total value of $450,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 21,023 shares of company stock valued at $5,230,857. 0.65% of the stock is owned by company insiders.

ResMed Price Performance

Shares of NYSE RMD opened at $222.11 on Tuesday. The company has a current ratio of 3.06, a quick ratio of 2.32 and a debt-to-equity ratio of 0.06. ResMed Inc. has a twelve month low of $216.68 and a twelve month high of $293.81. The stock has a 50 day moving average of $235.91 and a two-hundred day moving average of $247.55. The stock has a market cap of $32.36 billion, a P/E ratio of 21.97, a P/E/G ratio of 1.45 and a beta of 0.93.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Friday, January 30th. The medical equipment provider reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The company had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the previous year, the business earned $2.43 earnings per share. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. On average, research analysts forecast that ResMed Inc. will post 11.05 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Shareholders of record on Thursday, February 12th were paid a $0.60 dividend. The ex-dividend date was Thursday, February 12th. This represents a $2.40 dividend on an annualized basis and a yield of 1.1%. ResMed’s payout ratio is currently 23.74%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on ResMed from $265.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Friday, January 30th. KeyCorp lowered their price objective on ResMed from $302.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday. Weiss Ratings downgraded ResMed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 19th. JPMorgan Chase & Co. assumed coverage on ResMed in a research report on Wednesday, April 15th. They set an “overweight” rating for the company. Finally, Stifel Nicolaus boosted their price objective on ResMed from $260.00 to $265.00 and gave the stock a “hold” rating in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $294.55.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.